Port Delivery System | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

61,761 results for “Port Delivery System”

Trials

View all 47176 →

Extension Study for the Port Delivery System With Ranibizumab (Portal)

1,000 participants · First posted Sep 25, 2018

Active, not recruiting

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

174 participants · First posted Aug 7, 2020

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

188 participants · First posted Apr 21, 2021

Drugs

View all 967 →

V-404

drug delivery system

OLipHEX delivery system

Organizations

View all 487 →

Port Said University

Egypt

Port Jervis Laboratories, Inc.

United States

iVeena Delivery Systems, Inc.

United States

News

View all 13131 →

Port Delivery System Demonstrates 7-Year Vision Preservation in Wet AMD Patients

Chugai's Port Delivery System with Ranibizumab Shows Promise in Japanese Phase I/II Trial for Retinal Diseases

CHMP Recommends EU Approval of Roche's Susvimo, First Continuous Delivery Treatment for Neovascular AMD

Page 1 of 6177